Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Factors Linked with Early Initiation of DMD Treatment

Curr Med Res Opin; ePub 2018 Mar 1; Edwards, et al

In this population of patients initiating disease-modifying drug (DMD) treatment within 2 years of multiple sclerosis (MS) diagnosis, mean time to first DMD was 112.6 days, a recent study found. Identifying factors associated with delayed treatment may provide better understanding of the reasons for delay, leading to improved disease management. This retrospective cohort study included newly diagnosed patients with MS from a US administrative claims database, aged 18–65 years, with a first MS diagnosis between January 1, 2007, and June 30, 2013. Researchers found:

  • 37.4% of patients initiated DMD treatment within 2 years of MS diagnosis and were included in the primary analysis (n= 7,124).
  • Mean (standard deviation [SD]) time from MS diagnosis to first DMD was 112.6 (148.3) days (median=51); 30.7% received first DMD in <30 days, 55.1% in <60 days, and 18.5% not until ≥180 days after diagnosis.
  • Logistic regression found that younger age; not living in the Northeast; diagnoses of balance disorders, numbness, and optical neuritis; the absence of musculoskeletal diagnoses; and a neurologist visit or MRI within 90 days before diagnosis were associated with DMD initiation within 60 days.

Citation:

Edwards NC, Munsell M, Menzin J, Phillips AL. Factors associated with early initiation of disease-modifying drug treatment in newly diagnosed patients with multiple sclerosis. [Published online ahead of print March 1, 2018]. Curr Med Res Opin. doi:10.1080/03007995.2018.1447452.

This Week's Must Reads

Readmission Rates After Thrombectomy for Stroke , J Stroke Cerebrovasc Dis; ePub 2018 Jul 3; Ramchand, et al

Admissions for Psychotic Episodes, Epilepsy Linked , Epilepsia; ePub 2018 Jul 4; Rossi, Kim, et al

Gender and Cognition in Overweight Adults with T2D, Alzheimers Dement; ePub 2018 Jul 4; Espeland, et al

Subjective Improvements in Sleep Apnea Examined, Sleep Med; ePub 2018 Jul 4; Bhat, Gupta, et al

FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3

Must Reads in Multiple Sclerosis

Brain Volume Loss as Therapeutic Response Marker , JAMA Neurology; ePub 2018 Jul 2; Andorra, et al

Assessing Environmental Factors and Risk of MS, Mult Scler Relat Disord; ePub 2018 Jun 23; Mowry, et al

Fear of Falling Impacts Leisure-Time Activity in MS, Gait Posture; ePub 2018 Jun 30; Kalron, Aloni, et al

Identifying Anxiety Symptoms in Multiple Sclerosis, Arch Phys Med Rehab; ePub 2018 Jun 30; Hughes, et al

Spinal Cord Volume Loss: Marker of MS Progression, Neurology; ePub 2018 Jun 27; Tsagkas, Magon, et al